The DEA's June 29 Hearing Could Reshape American Cannabis Law Forever

Thirty-Four Days Away from the Most Important Cannabis Hearing in History

On June 29, 2026, at 9 a.m. Eastern Time, inside the DEA Hearing Facility at 700 Army Navy Drive in Arlington, Virginia, a proceeding will begin that could fundamentally alter the legal landscape for cannabis in the United States. The hearing, scheduled to conclude no later than July 15, will consider whether cannabis broadly — not just state-licensed medical products or FDA-approved drugs — should be moved from Schedule I to Schedule III of the Controlled Substances Act.

The stakes are difficult to overstate. Schedule I classification has defined cannabis's legal status since the Controlled Substances Act of 1970. It places marijuana in the same category as heroin and LSD, designating it as having no accepted medical use and a high potential for abuse. Every federal enforcement action, every banking restriction, every research barrier, and every employment discrimination case in cannabis history traces back to this classification.

Moving all cannabis to Schedule III would not legalize it. But it would remove the most punishing federal constraints on an industry that now operates legally in 38 states and generates over $30 billion in annual revenue.

What Has Already Changed

To understand the June 29 hearing, you must first understand what happened on April 23, 2026. On that date, the Department of Justice issued a final order reclassifying two specific categories of cannabis to Schedule III: FDA-approved products containing marijuana and marijuana products regulated by a state medical marijuana license.

This partial rescheduling was significant. It immediately relieved qualifying cannabis businesses of the crushing burden of Internal Revenue Code Section 280E, which prohibited businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. For companies operating in states with medical cannabis programs, the 280E relief alone represented a financial lifeline worth hundreds of millions of dollars collectively.

But the April order was deliberately narrow. Recreational cannabis in adult-use states remained in Schedule I. Businesses operating solely in the adult-use market received no 280E relief. Cannabis not covered by a state medical license — including the entire hemp-derived product category — stayed in legal limbo.

The June 29 hearing addresses the broader question: should cannabis itself, regardless of its specific regulatory context, move to Schedule III?

The Case for Full Rescheduling

Proponents of moving all cannabis to Schedule III marshal several categories of evidence. The medical argument is perhaps the most established. Over 100 peer-reviewed cannabis studies published in 2026 alone have documented therapeutic applications ranging from chronic pain management and chemotherapy-induced nausea to anxiety, insomnia, and inflammatory conditions. The FDA's own scientists have acknowledged that cannabis has accepted medical uses, a finding that directly contradicts the Schedule I classification criteria.

The economic argument is equally compelling. The legal cannabis industry employs over 400,000 Americans and generates billions in tax revenue for state and local governments. Schedule I status creates a surreal regulatory environment where state-legal businesses cannot access federal banking services, cannot deduct business expenses, and operate under the constant theoretical threat of federal prosecution. Moving to Schedule III would normalize business operations without requiring full legalization.

The criminal justice argument resonates across political lines. Despite shifting state laws, cannabis remains the most commonly cited substance in federal drug arrests. Rescheduling would not eliminate federal cannabis enforcement, but it would significantly reduce the severity of penalties and align federal policy more closely with the reality that most Americans live in jurisdictions where some form of cannabis use is legal.

The Case Against — Or at Least for Caution

Opponents of broad rescheduling raise legitimate concerns that deserve honest examination. The most substantive is the regulatory gap argument. Schedule III substances are subject to federal oversight by the DEA and FDA, including manufacturing standards, prescription requirements, and distribution controls. The current state-regulated cannabis market was not designed to comply with these federal frameworks, and imposing Schedule III requirements could create chaos during the transition.

Public health advocates worry about the signal that rescheduling sends. While cannabis is significantly less harmful than many legal substances, it is not risk-free. Youth access, impaired driving, and the potential for cannabis use disorder in vulnerable populations are genuine concerns that a more permissive federal stance could exacerbate if not accompanied by robust regulatory safeguards.

The pharmaceutical industry has its own reservations. Companies that have invested billions in developing FDA-approved cannabis-derived drugs — like Epidiolex and the recently designated VER-01 — fear that broad rescheduling could undermine their regulatory advantage. If dispensary cannabis becomes Schedule III alongside their heavily tested pharmaceutical products, the commercial incentive for rigorous clinical development diminishes.

Who Is at the Table

The May 28 deadline for filing written notice of intent to participate in the hearing is just two days away, and the roster of expected participants reflects the enormity of what is at stake.

Cannabis industry trade groups — including the National Cannabis Industry Association, the Cannabis Trade Federation, and state-level associations from major markets — have mobilized legal teams to present testimony on the economic and practical benefits of rescheduling. Major multi-state operators are expected to submit evidence on the impact of 280E and banking restrictions on their operations.

On the other side, law enforcement organizations, substance abuse prevention groups, and some pharmaceutical companies have indicated they will argue for maintaining the current classification or implementing a more cautious reclassification approach.

Medical and scientific organizations occupy a nuanced middle ground. Several major medical associations have endorsed rescheduling in principle while calling for the development of federal quality and safety standards as a prerequisite. Research institutions are expected to testify about the barriers that Schedule I status has imposed on clinical investigation.

What Schedule III Would and Would Not Do

The most common misconception about rescheduling is that it would legalize recreational cannabis at the federal level. It would not. Schedule III status means a substance has accepted medical use and a lower potential for abuse than Schedule I or II drugs. Other Schedule III substances include testosterone, ketamine, and anabolic steroids — all legal with a prescription but still controlled.

What Schedule III would do is transformative nonetheless. Section 280E would no longer apply to any cannabis business, not just medical operators. Federal banking access would become significantly easier, though not automatic — banks would still need to conduct due diligence, but the fundamental legal barrier to serving cannabis businesses would be removed. Research would be dramatically simplified, as Schedule III substances face far fewer investigational hurdles than Schedule I.

Crucially, Schedule III status would not preempt state law. States that have legalized adult-use cannabis would continue to regulate their markets under existing frameworks. States that have not legalized cannabis would remain free to maintain prohibition. The federal change would remove the conflict between federal and state law that has defined cannabis policy for decades, but it would not override state-level decisions in either direction.

The Timeline After the Hearing

The June 29 hearing is not a vote. It is an administrative proceeding that will generate a record of testimony and evidence. After the hearing concludes by July 15, the DEA Administrator will issue a final decision based on the record. There is no statutory deadline for that decision, but the expedited nature of the proceeding — mandated by President Trump's December 2025 Executive Order — suggests the DEA intends to act within months rather than years.

If the DEA moves forward with broad rescheduling, the rule would undergo a public comment period before taking effect. Legal challenges are virtually certain regardless of the outcome, and cases could reach the federal appellate courts within a year.

The most likely timeline for a final rescheduling decision, if it happens, is late 2026 or early 2027. For an industry that has waited over fifty years for this moment, a few more months of patience may be the final stretch.

What This Means for You

If you are a cannabis consumer, a patient, a business owner, or simply a citizen interested in drug policy, the June 29 hearing matters. It represents the most serious, most structured, and most politically viable opportunity for federal cannabis reform since the Controlled Substances Act was enacted.

The hearing will not resolve every contradiction in American cannabis policy. It will not end the patchwork of state regulations, resolve the hemp versus cannabis divide, or address the legacy of prohibition-era criminal convictions. But it could remove the foundational legal barrier that has distorted cannabis policy for over half a century.

The hearing begins in thirty-four days. The participation deadline is in two. The outcome will echo for decades.